Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Colorectal Neoplasms 24Pancreatic Neoplasms 21Neoplasm Metastasis 16Neuroblastoma 8Rhabdomyosarcoma 6Lung Neoplasms 6Colonic Neoplasms 6Rectal Neoplasms 5Neoplasms 5Esophageal Squamous Cell Carcinoma 5Stomach Neoplasms 4Small Cell Lung Carcinoma 4Sarcoma, Ewing 4Sarcoma 4Esophageal Neoplasms 4Adenocarcinoma Of Esophagus 4Endometrial Neoplasms 3Cholangiocarcinoma 3Carcinoma, Non-Small-Cell Lung 3Biliary Tract Neoplasms 3Wilms Tumor 2Pathologic Complete Response 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Kidney Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2Glioma 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Breast Neoplasms 2

Interventions

trastuzumab deruxtecan 1sacituzumab govitecan 1Temozolomide 1Social Determinants of Health 1Methylprednisolone 1Irinotecan 1Cefixime 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Irinotecan × 90 days × Clear all
NCT00093353 2026-04-14

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
30 enrolled
CNS

Diarrhea, Neuroblastoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡